Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Aug 26, 2009

Affymetrix and Beckman Coulter Ally to Provide Automated Target-Prep Solutions

  • Affymetrix and Beckman Coulter plan on offering researchers co-developed products that provide optimized, robust solutions and end-to-end support for genomic research. This platform will provide researchers with standardized systems that include all components necessary to run Affymetrix genotyping and gene-expression assays.

    The goal of the partnership is to yield an expanding list of Affymetrix-validated automated target-preparation methods, developed on an Affymetrix-specific configuration of Beckman Coulter’s Biomek FXp Dual Arm Multichannel with Span 8 Liquid Handler.

    Major benefits will include the flexibility to process samples using Affymetrix GeneChip® Arrays or Array Plates with a single method, user friendly interface, rapid implementation of new methods, a validated platform, elimination of costly mistakes, and delivery of high-quality results, the firms report.

    “Beckman Coulter’s long history in manufacturing quality automation platforms with proven reliability make the company the ideal partner for developing automated target-prep assays,” comments Kevin King, president and CEO of Affymetrix. “These products not only provide a much needed target-prep solution for our large installed base of GeneChip Array cartridge users, but very importantly, this agreement aligns with our strategic goals to re-engineer the Affymetrix platform. With automated target-prep robotics in front of our GeneTitan™ System, our customers will benefit from walk-away automation from prepared samples all the way through array processing and data generation.”


Related content

Be sure to take the GEN Poll

Cancer vs. Zika: What Worries You Most?

While Zika continues to garner a lot of news coverage, a Mayo Clinic survey reveals that Americans believe the country’s most significant healthcare challenge is cancer. Compared to other diseases, does the possibility of developing cancer worry you the most?

More »